Lorenzo Azzi

Lorenzo Azzi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Infection
Verified
Journal Article
Open access
LALorenzo Azzi
Lorenzo Azzi
GCGiulio Carcano
Giulio Carcano
Francesco GianfagnaFrancesco Gianfagna
Francesco Gianfagna
PGPaolo Grossi
Paolo Grossi
DGDaniela Dalla Gasperina
Daniela Dalla Gasperina
Andreina BajAndreina Baj
Andreina Baj
This study analyzed salivary samples of COVID-19 patients and compared the results with their clinical and laboratory data. Salivary samples of 25 COVID-19 patients were analyzed by rRT-PCR. The following data were collected: age, sex, comorbidities, drugs. Lactate dehydrogenase (LDH) and ultrasensitive reactive C protein (usRCP) values were registered on the same day when a salivary swab was collected. Prevalence of positivity in saliva and association between clinical data and the cycle threshold as a semiquantitative indicator of viral load were considered. Twenty-five subjects were recruited into this study, 17 males and 8 females. The mean age was 61.5 +/- 11.2 years. Cardiovascular and/or dysmetabolic disorders were observed in 65.22% of cases. All the samples tested positive for the presence of SARS-CoV-2, while there was an inverse association between LDH and Ct values. Two patients showed positive salivary results on the same days when their pharyngeal or respiratory swabs showed conversion. Saliva is a reliable tool to detect SARS-CoV-2. The role of saliva in COVID-19 diagnosis could not be limited to a qualitative detection of the virus, but it may also provide information about the clinical evolution of the disease.

23 December 2021 in EBioMedicine
Verified
Journal Article
Open access
LALorenzo Azzi
Lorenzo Azzi
DGDaniela Dalla Gasperina
Daniela Dalla Gasperina
GVGiovanni Veronesi
Giovanni Veronesi
MSMariam Shallak
Mariam Shallak
GIGiuseppe Ietto
Giuseppe Ietto
GFGreta Forlani
Greta Forlani
Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing antibodies in serum protecting against COVID-19, it has not been studied in detail whether it could generate specific immunity at mucosal sites, which represent the primary route of entry of SARS-CoV-2. Samples of serum and saliva of 60 BNT162b2-vaccinated healthcare workers were collected at baseline, two weeks after the first dose and two weeks after the second dose. Anti-S1-protein IgG and IgA total antibodies titres and the presence of neutralizing antibodies against the Receptor Binding Domain in both serum and saliva were measured by quantitative and by competitive ELISA, respectively. Complete vaccination cycle generates a high serum IgG antibody titre as a single dose in previously infected seropositive individuals. Serum IgA concentration reaches a plateau after a single dose in seropositive individuals and two vaccine doses in seronegative subjects. After the second dose IgA level was higher in seronegative than in seropositive subjects. In saliva, IgG level is almost two orders of magnitude lower than in serum, reaching the highest values after the second dose. IgA concentration remains low and increases significantly only in seropositive individuals after the second dose. Neutralizing antibody titres were much higher in serum than in saliva. The mRNA BNT162b2 vaccination elicits a strong systemic immune response by drastically boosting neutralizing antibodies development in serum, but not in saliva, indicating that at least oral mucosal immunity is poorly activated by this vaccination protocol, thus failing in limiting virus acquisition upon its entry through this route. This work was funded by the Department of Medicine and Surgery, University of Insubria, and partially supported by Fondazione Umberto Veronesi (COVID-19 Insieme per la ricerca di tutti, 2020).

31 October 2020 in Journal of Dental Research
Verified
Journal Article
Open access
PDF file
LALorenzo Azzi
Lorenzo Azzi
VMV. Maurino
V. Maurino
ABA. Baj
A. Baj
MDM. Dani
M. Dani
ADA. D’aiuto
A. D’aiuto
TAT. Alberio
T. Alberio
The diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection relies on the detection of viral RNA by real-time reverse transcription polymerase chain reaction (rRT-PCR) performed with respiratory specimens, especially nasopharyngeal swabs. However, this procedure requires specialized medical personnel, centralized laboratory facilities, and time to provide results (from several hours up to 1 d). In addition, there is a non-negligible risk of viral transmission for the operator who performs the procedure. For these reasons, several studies have suggested the use of other body fluids, including saliva, for the detection of SARS-CoV-2. The use of saliva as a diagnostic specimen has numerous advantages: it is easily self-collected by the patient with almost no discomfort, it does not require specialized health care personnel for its management, and it reduces the risks for the operator. In the past few months, several scientific papers, media, and companies have announced the development of new salivary tests to detect SARS-CoV-2 infection. Posterior oropharyngeal saliva should be distinguished from oral saliva, since the former is a part of respiratory secretions, while the latter is produced by the salivary glands, which are outside the respiratory tract. Saliva can be analyzed through standard (rRT-PCR) or rapid molecular biology tests (direct rRT-PCR without extraction), although, in a hospital setting, these procedures may be performed only in addition to nasopharyngeal swabs to minimize the incidence of false-negative results. Conversely, the promising role of saliva in the diagnosis of SARS-CoV-2 infection is highlighted by the emergence of point-of-care technologies and, most important, point-of-need devices. Indeed, these devices can be directly used in workplaces, airports, schools, cinemas, and shopping centers. An example is the recently described Rapid Salivary Test, an antigen test based on the lateral flow assay, which detects the presence of the virus by identifying the spike protein in the saliva within a few minutes.

1 September 2020 in Journal of Infection
Verified
Journal Article
Closed access
LALorenzo Azzi
Lorenzo Azzi
Andreina BajAndreina Baj
Andreina Baj
TATiziana Alberio
Tiziana Alberio
Marta LualdiMarta Lualdi
Marta Lualdi
GVGiovanni Veronesi
Giovanni Veronesi
Mauro FasanoMauro Fasano
Mauro Fasano

21 January 2020 in Materials
Verified
Journal Article
Open access
PDF file
Davide FarronatoDavide Farronato
Davide Farronato
PPPietro Pasini
Pietro Pasini
AOAndrea Alain Orsina
Andrea Alain Orsina
Mattia ManfrediniMattia Manfredini
Mattia Manfredini
LALorenzo Azzi
Lorenzo Azzi
Marco FarronatoMarco Farronato
Marco Farronato
Background: Optimal aesthetic implant restoration is a combination of a visually pleasing prosthesis and adequate surrounding peri-implant soft tissue architecture. This study describes the influence of the residual buccal bone thickness (BBT), measured at the time of implant placement, on the soft tissue maturation during three years of follow-up. Methods: Seventy-eight implants were enrolled in the present study. The BBT was assessed at the surgical stage and each case assigned to Group 1 (BBT values ≤0.5 mm), Group 2 (BBT values >0.5 and 0.5 and <1.5 mm, the buccal gum also showed recession of 0.64 ± 0.29 mm. In contrast, for BBT values ≥1.5 mm, the buccal gum showed coronal growth of 0.77 ± 0.22 mm. The differences between the groups were significant (p ≤ 0.01) at all times. Conclusion: The BBT at the time of implant placement was found to affect the buccal gingival margin stability over three years of observation.

26 August 2014 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
FSFrancesco Spadari
Francesco Spadari
PVPaolo Venesia
Paolo Venesia
LALorenzo Azzi
Lorenzo Azzi
GVGiovanni Veronesi
Giovanni Veronesi
DCDario Costantino
Dario Costantino
LTLucia Tettamanti
Lucia Tettamanti